A second major theme is the potential for biomarkers to enhance clinical management of AKI through earlier diagnosis, guiding treatment decisions, and improving outcomes.Peabody et al. (2022) conducted an insightful randomized controlled trial demonstrating that a novel urinary biomarker, L-FABP, could significantly improve cardiologists’ ability to diagnose and treat contrast-induced AKI (CI-AKI) during procedures [62]. The gene discussed is FABP1; the disease is acute kidney injury.